Department of Hematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Department of Pediatric Surgery, Guangzhou Women and Children's Medical Center, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou Medical University, Guangzhou, Guangdong, China.
Cancer Rep (Hoboken). 2024 Jul;7(7):e2136. doi: 10.1002/cnr2.2136.
Glioma is the most prevalent pediatric central nervous system malignancy. RAN, member RAS oncogene family (RAN), is a key signaling molecule that regulates the polymerization of microtubules during mitosis. RAN binding protein 2 (RANBP2) is involved in DNA replication, mitosis, metabolism, and tumorigenesis. The effects of RAN and RANBP2 gene polymorphisms on glioma susceptibility in Chinese children are currently unknown.
This study aimed to evaluate the association between RAN and RANBP2 gene polymorphisms and glioma susceptibility in Chinese children.
We recruited 191 patients with glioma and 248 children without cancer for this case-control study. Polymerase chain reaction-based TaqMan was applied to gene sequencing and typing. Logistic regression model-calculated odds ratio and 95% confidence interval were used to verify whether the gene polymorphisms (RAN rs56109543 C>T, rs7132224 A>G, rs14035 C>T, and RANBP2 rs2462788 C>T) influence glioma susceptibility. Based on age, gender, tumor subtype, and clinical stage, stratified analyses of risk and protective genotypes were conducted. p values for mutant genotype analyses were all >0.05, indicating no significant correlation between these gene polymorphisms and glioma risk.
RAN and RANBP2 gene polymorphisms were not found to be statistically significantly associated with glioma susceptibility in Chinese children. Other potential functional gene polymorphism loci of RAN and RANBP2 will need to be evaluated in the search for novel glioma biomarkers.
神经胶质瘤是最常见的小儿中枢神经系统恶性肿瘤。RAN,RAS 癌基因家族成员,是一种关键的信号分子,在有丝分裂过程中调节微管的聚合。RAN 结合蛋白 2(RANBP2)参与 DNA 复制、有丝分裂、代谢和肿瘤发生。RAN 和 RANBP2 基因多态性对中国儿童患神经胶质瘤易感性的影响尚不清楚。
本研究旨在评估 RAN 和 RANBP2 基因多态性与中国儿童神经胶质瘤易感性的关系。
我们进行了这项病例对照研究,共招募了 191 名神经胶质瘤患者和 248 名无癌症的儿童。聚合酶链反应-基于 TaqMan 的基因测序和分型。逻辑回归模型计算的比值比和 95%置信区间用于验证基因多态性(RAN rs56109543 C>T、rs7132224 A>G、rs14035 C>T 和 RANBP2 rs2462788 C>T)是否影响神经胶质瘤易感性。根据年龄、性别、肿瘤亚型和临床分期,对风险和保护基因型进行分层分析。突变基因型分析的 p 值均>0.05,表明这些基因多态性与神经胶质瘤风险之间无显著相关性。
RAN 和 RANBP2 基因多态性与中国儿童神经胶质瘤易感性无统计学显著相关性。需要评估 RAN 和 RANBP2 的其他潜在功能基因多态性位点,以寻找新的神经胶质瘤生物标志物。